Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Average Target Price from Analysts

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have been assigned a consensus recommendation of “Hold” from the seven research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $55.50.

A number of analysts have weighed in on the company. Barclays set a $5.00 price objective on Tvardi Therapeutics and gave the stock an “equal weight” rating in a research report on Monday, October 13th. Cantor Fitzgerald downgraded Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 13th. BTIG Research lowered their price objective on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating on the stock in a research report on Monday, October 13th. Wall Street Zen raised shares of Tvardi Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. Finally, Raymond James Financial downgraded shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 14th.

Tvardi Therapeutics Price Performance

TVRD stock opened at $4.00 on Wednesday. The company has a market cap of $37.52 million, a price-to-earnings ratio of -0.42 and a beta of 0.11. The company has a fifty day moving average price of $4.45 and a 200 day moving average price of $20.02. Tvardi Therapeutics has a 12 month low of $3.74 and a 12 month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.24. Tvardi Therapeutics had a negative net margin of 585.37% and a negative return on equity of 282.16%.

Institutional Investors Weigh In On Tvardi Therapeutics

Institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. purchased a new position in shares of Tvardi Therapeutics in the 2nd quarter valued at about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Tvardi Therapeutics during the second quarter worth about $43,000. Headlands Technologies LLC purchased a new position in Tvardi Therapeutics in the second quarter valued at about $80,000. New York State Common Retirement Fund purchased a new position in Tvardi Therapeutics in the second quarter valued at about $92,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Tvardi Therapeutics during the 3rd quarter valued at approximately $318,000. 44.66% of the stock is currently owned by hedge funds and other institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.